Skip to main content

Table 3 Comparison of changes in volume and IPSS for different patterns of hyperplasia, presence of AdBPH, technical success of embolization, and different volume groups

From: Influence of benign prostatic hyperplasia patterns detected with MRI on the clinical outcome after prostatic artery embolization

 

IPSS reduction

Volume reduction

mean

SD

mean

SD

BPH type according to Wasserman

 type 1 (n = 18)

56%

33%

25%

11%

 type 2 (n = 5)

45%

34%

26%

10%

 type 3 (n = 15)

54%

24%

22%

14%

 type 4 (n = 1)

45%

na

28%

na

 type 5 (n = 17)

38%

56%

25%

13%

 p-value*

0.60

0.88

simplified BPH classification

 preurethral (n = 27)

52%

33%

25%

11%

 retrourethral (n = 9)

50%

29%

29%

10%

 biurethral (n = 30)

45%

49%

22%

14%

 p-value*

0.59

0.88

PAE unilateral vs. bilateral

 Unilateral (n = 7)

21%

85%

14%

14%

 Bilateral (n = 59)

52%

29%

26%

12%

 p-value**

 < 0.01

 < 0.01

presence of AdBPH

 non-AdBPH (n = 13)

36%

38%

21%

13%

 AdBPH (n = 53)

51%

39%

25%

9%

 p-value**

 < 0.01

 < 0.01

volume groups

 < 100 ml (n = 43)

43%

43%

23%

12%

 > 100 ml (n = 23)

59%

27%

26%

13%

 p-value**

 < 0.01

 < 0.04

  1. AdBPH Adenomatous-dominant benign prostatic hyperplasia, BPH Benign prostatic hyperplasia, IPSS International prostatic symptoms score, SD standard deviation, PAE prostatic artery embolization
  2. *Kruskall-Wallis-test was used to check for statistical significance
  3. **Wilcoxon-rank-sum-test was used to check for statistical significance